C. Gluud and L. Gluud, Evidence based diagnostics, BMJ, vol.330, issue.7493, pp.724-730, 2005.
DOI : 10.1136/bmj.330.7493.724

G. Guyatt, D. Sackett, and D. Cook, Users guide to the medical literature 2. How to use an article about therapy or prevention. A. Are the results of the study valid? JAMA, pp.2598-2601, 1993.
DOI : 10.1001/jama.284.10.1290

K. Schulz, I. Chalmers, R. Hayes, and D. Altman, Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials, JAMA: The Journal of the American Medical Association, vol.273, issue.5, pp.408-420, 1995.
DOI : 10.1001/jama.273.5.408

L. Kjaergard, J. Villumsen, and C. Gluud, Reported Methodologic Quality and Discrepancies between Large and Small Randomized Trials in Meta-Analyses, Annals of Internal Medicine, vol.135, issue.11, pp.982-89, 2001.
DOI : 10.7326/0003-4819-135-11-200112040-00010

L. Wood, M. Egger, L. Gluud, K. Schulz, P. Jüni et al., Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study, BMJ, vol.336, issue.7644, pp.601-606, 2008.
DOI : 10.1136/bmj.39465.451748.AD

L. Gluud, Bias in Clinical Intervention Research, American Journal of Epidemiology, vol.163, issue.6, pp.493-501, 2006.
DOI : 10.1093/aje/kwj069

URL : http://aje.oxfordjournals.org/cgi/content/short/163/6/493

C. Gluud, The culture of designing hepato-biliary randomised trials, Journal of Hepatology, vol.44, issue.3, pp.607-622, 2006.
DOI : 10.1016/j.jhep.2005.12.006

J. Wetterslev, K. Thorlund, J. Brok, and C. Gluud, Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis, Journal of Clinical Epidemiology, vol.61, issue.1
DOI : 10.1016/j.jclinepi.2007.03.013

K. Thorlund, P. Devereaux, J. Wetterslev, G. Guyatt, J. Ioannidis et al., Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?, International Journal of Epidemiology, vol.38, issue.1, pp.276-86, 2009.
DOI : 10.1093/ije/dyn179

URL : http://ije.oxfordjournals.org/cgi/content/short/38/1/276

S. Garattini and V. Bertelé, How can we regulate medicines better?, BMJ, vol.335, issue.7624, pp.803-808, 2007.
DOI : 10.1136/bmj.39281.615706.94

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034743

M. Alaoui-ismaili, P. Lomedico, and S. Jindal, Chemical genomics: discovery of disease genes and drugs. Drug Discovery Today, pp.292-294, 2002.
DOI : 10.1016/s1359-6446(02)02185-2

T. Simon, C. Verstuyft, M. Mary-krause, L. Quteineh, E. Drouet et al., Genetic Determinants of Response to Clopidogrel and Cardiovascular Events, New England Journal of Medicine, vol.360, issue.4, pp.363-375, 2009.
DOI : 10.1056/NEJMoa0808227

J. Demotes-mainard and C. Ohmann, European Clinical Research Infrastructures Network: promoting harmonisation and quality in European clinical research, The Lancet, vol.365, issue.9454, pp.107-115, 2005.
DOI : 10.1016/S0140-6736(05)17720-4

J. Demotes-mainard, Towards a European Clinical Research Infrastructures Network: The ECRIN Programme, Th??rapie, vol.59, issue.1, pp.151-153, 2004.
DOI : 10.2515/therapie:2004029

G. Remuzzi, A. Schieppati, J. Boissel, S. Garattini, and R. Horton, Independent clinical research in Europe, The Lancet, vol.364, issue.9446, pp.17232-17238, 2004.
DOI : 10.1016/S0140-6736(04)17360-1

A. Hemminki and P. Kellokumpu-lehtinen, Harmful impact of EU clinical trials directive, BMJ, vol.332, issue.7540, pp.501-503, 2006.
DOI : 10.1136/bmj.332.7540.501

M. Hartmann and F. Hartmann-vareilles, The clinical trials directive: how is it affecting Europe's non-commercial research? PLOS Clinical Trials, p.13, 2006.

A. Mcmahon, D. Conway, T. Macdonald, and G. Mcinnes, The Unintended Consequences of Clinical Trials Regulations, PLoS Medicine, vol.6, issue.11, pp.1000131-1000141, 2009.
DOI : 10.1371/journal.pmed.1000131

C. Kubiak, F. De-andres-trelles, W. Kuchinke, K. Huemer, S. Thirstrup et al., Common definition for categories of clinical research: a prerequisite for a survey on regulatory requirements by the European Clinical Research Infrastructures Network (ECRIN), Trials, vol.10, issue.1, p.95, 2009.
DOI : 10.1186/1745-6215-10-95

URL : https://hal.archives-ouvertes.fr/inserm-00663586

M. Project, Risk-adapted Approaches to the Management of Clinical Trials of Investigational Medicinal Products

O. Brosteanu, P. Houben, K. Ihrig, C. Ohmann, U. Paulus et al., Risk analysis and risk adapted on-site monitoring in noncommercial clinical trials, Clinical Trials, vol.3, issue.279, pp.585-596, 2009.
DOI : 10.1177/1740774509347398

A. Italiana and D. Farmaco, AIFA):[http

. Gluud, Typical investigational medicinal products follow relatively uniform regulations in 10 European Clinical Research Infrastructures Network (ECRIN) countries. Trials 2012 13:27. Submit your next manuscript to BioMed Central and take full advantage of
DOI : 10.1186/1745-6215-13-27

URL : https://hal.archives-ouvertes.fr/inserm-00692048